Clinical trials: Metastasis Colorectal Cancer
Liver Metastases, Recurrent Colon Cancer
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00645710
- Testing
- gemcitabine hydrochloride, floxuridine, proteomic profiling
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer (CRC)
Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study
Colorectal cancer (CRC) is one of the most common malignant tumors. With the rapid development of China's economy, people's living standards have been significantly improved, and lifestyles and dietary structures have changed.
- Trial name
- NCT06882915
- Testing
- Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Colorectal Cancer, Reaction - Mixed Vaccine
Mix Vaccine for Metastatic Colorectal Cancer
The aim of this study is the safety and efficacy of mix vaccine to small metastases of colorectal cancer.
- Trial name
- NCT03357276
- Testing
- Mix vaccine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Colorectal Cancer
A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
This 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment in patients with locally…
- Trial name
- NCT00118755
- Testing
- capecitabine, Oxaliplatin, bevacizumab
- Volunteers
- 435 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Colorectal Cancer, Lung Metastases
CirculAting Tumor DNA in Patients DIagnosed With Lung Metastasis From Colorectal Cancer: candiDate Selection for Local AblaTive thErapy
The investigators will detect circulating tumor DNA in blood of patients with lung metastases from colorectal cancer using NGS technology and intend to use it for predicting the outcome of local treatment (surgery or radiation)…
- Trial name
- CANDIDATE (NCT04704960)
- Testing
- Diagnostic Test: liquid biopsy
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
KRAS and NRAS Wild-type Colorectal Cancer
Regorafenib + Panitumumab for Colorectal Cancers
Evaluate the safety of regorafenib and panitumumab
- Trial name
- NCT02199223
- Testing
- regorafenib + panitumumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Utah
Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer
TCR1020-CD8 T Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1020-CD8 T cells in patients with KRAS-mutated cancers.
- Trial name
- NCT06707896
- Testing
- TCR1020-CD8 T cells
- Sponsor
- University of Pennsylvania
Colorectal Cancer Metastatic
FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
The purpose of this interventional study is to assess the progression free survival (one year) of patients with treatment of FOLFIRI and cetuximab, combined with an optional dermal prophylaxis. Further Objectives: 1.
- Trial name
- DERMATUX (NCT01315990)
- Testing
- FOLFIRI + Cetuximab
- Where
- Germany
- Volunteers
- 165 people
- Sponsor
- Dr. Carl Schimanski
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that that may have spread from where it first started to nearby tissue…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02298959
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 9 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
A Study of Picoplatin in Colorectal Cancer
Colorectal cancer is a type of cancer that begins in the large intestine (colon) or the rectum (end of the colon). Several drugs are often given in combination to treat colorectal cancer.
- Trial name
- NCT00478946
- Testing
- (FOLPI) Picoplatin with 5-FU and Leucovorin, FOLPI, FOLFOX
- Where
- 16 sites in Russia
- Volunteers
- 43 people
- Sponsor
- Poniard Pharmaceuticals
Colorectal Liver Metastasis
Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer
the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).
- Trial name
- ARMANI (NCT04678583)
- Testing
- Resection of colorectal liver metastases
- Where
- 37 sites in Germany
- Volunteers
- 240 people
- Sponsor
- Technische Universität Dresden
Octogenarian Patients With Non-metastatic Resectable Colorectal Cancer
SGA-OCRC: Prediction of 90-Day Major Adverse Postoperative Outcomes in Octogenarians With Resectable Colorectal Cancer
Octogenarian patients with colorectal cancer are a growing population with substantial heterogeneity in frailty, functional reserve, nutritional status, and comorbidity.
- Trial name
- NCT07903129
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colon Cancer, Rectal Cancer
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as…
- Trial name
- SCOTI (NCT05806931)
- Testing
- TAS-102, oxaliplatin, irinotecan with bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started…
- Conditions
- Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
- Trial name
- NCT02314169
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 56 sites in United States, Canada
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Rectal Adenocarcinoma, Brain Metastases
BRIANSTORM - Early Identification of Patients With Brain Metastases
A single arm observational study investigating the incidence of brain metastasis in patients with cancer recti and lung metastasis
- Trial name
- NCT05185557
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma
Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma
This study evaluates the feasibility of the combination of radiotherapy, chemotherapies (docetaxel, cisplatin and 5-fluorouracil) and spartalizumab (anti-PD-1 therapy) in patients with metastatic squamous cell anal carcinoma
- Trial name
- SPARTANA (NCT04894370)
- Testing
- Sample collection
- Where
- 5 sites in France
- Volunteers
- 34 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Colorectal Cancer, Colorectal Adenocarcinoma
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma
- Trial name
- NCT05200442
- Testing
- VS-6766/avutometinib, Cetuximab, Pill Diary
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Colorectal Cancer
Integrative Omics Analysis for Colorectal Cancer and Metastasis
The pathogenesis of Colorectal cancer (CRC) metastasis remains unclear.We collect clinical data from our center and use Integrative omics to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
- Trial name
- NCT05482529
- Testing
- Integrative omics
- Where
- China
- Volunteers
- 20 people
- Sponsor
- fan li
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.